DELFI Diagnostics, Inc., a developer of accessible blood-based AI tests that deliver a new way to enhance cancer detection, today announces the publication of groundbreaking data in the prestigious journal Cancer Discovery from the company’s L101 study, „Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection“. The report details the performance and potential of DELFI’s FirstLook Lung test. This milestone study, led by top researchers in the field, marks a significant advancement in aiding blood-based cancer detection.
The study, titled „Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection“ involved 958 participants, divided into a group for test training, and a separate independent group for test validation.
The authors detail the genomic elements derived through low-cost whole genome sequencing and show in the independent validation group that both sensitivity and specificity are remarkably consistent across patient subgroups that differ in demographics, comorbidities, and smoking history.
They then present the potential population health impact of the test if used to augment lung cancer screening in the United States, showing that even modest utilization would translate into meaningful shifts toward early-stage diagnosis and downstream reductions in lung cancer deaths.
https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-24-0519/745696/Clinical-validation-of-a-cell-free-DNA-fragmentome
